It appears Thermo Fisher Scientific (TMO) experienced some volatility in Q2, facing both downward movement and a price target cut from Stifel. However, the company’s stock jumped following strong results and a raised outlook. TMO unveiled new diagnostics solutions at the ADLM 2025 conference and showcased innovative microscopic technology at the M&M Conference. The company's stock showed strength despite being oversold, reminding investors of its value.
Thermo Fisher’s Q2 2025 exceeded expectations, and presented a positive 2025 guidance during its earnings conference call. The firm made significant moves in the market, including acquiring Sanofi's New Jersey manufacturing site and expanding their strategic partnership. They also gained FDA approval for their Oncomine Dx Express Test and a rapid cancer diagnostic tool.
Despite some negative trends and a downgrade at UBS due to life sciences R&D headwinds, TMO was favored by several high-profile investors like Jim Cramer, Evercore ISI, and Wells Fargo. Internally, EVP Pettiti sold 400 shares at $479.98 per share while CFO Stephen Williamson announced his retirement in early 2026.
In terms of future prospects, Thermo Fisher is exploring a $4 billion diagnostics sale and is speculated to be an attractively valued stock with recovery in sight.
Thermo Fisher Scientific TMO News Analytics from Thu, 06 Mar 2025 08:00:00 GMT to Sat, 02 Aug 2025 11:51:31 GMT - Rating 6 - Innovation 5 - Information 7 - Rumor 2
